মূল্য
দামগুলো আনুমানিক MRP এবং ফার্মেসিভেদে ভিন্ন হতে পারে। সর্বশেষ নথিভুক্ত দামের সাথে তুলনা করে ট্রেন্ড দেখানো হয়।
সব দামের পরিবর্তন →ইঙ্গিত ও ব্যবহার
Sotoxen এর জন্য নির্দেশিত:
ডোজ নির্দেশিকা
শুধুমাত্র নির্দেশিকা তথ্য
প্রদর্শিত ডোজগুলি সরকারি উৎসের সাধারণ নির্দেশিকা। ব্যক্তিগতকৃত ডোজের জন্য সর্বদা আপনার ডাক্তার বা ফার্মাসিস্টের পরামর্শ নিন।
প্রাপ্তবয়স্ক:
The recommended dosage of Sotorasib is 960 mg (eight 120 mg tablets) orally once daily until disease progression or unacceptable toxicity. Take Sotorasib at the same time each day with or without food. Swallow tablets whole. Do not chew, crush or split tablets. If a dose of Sotorasib is missed by more than 6 hours, take the next dose as prescribed the next day. Do not take 2 doses at the same time to make up for the missed dose. If vomiting occurs after taking Sotorasib, do not take an additional dose. Take the next dose as prescribed the next day.
পার্শ্বপ্রতিক্রিয়া
Two serious adverse effects were reported with the use of Sotoxen: hepatotoxicity and interstitial lung disease (ILD).Hepatotoxicity: Twenty-five percent of trial participants experienced liver dysfunction, resulting in elevated hepatic transaminases, elevated bilirubin, and drug-induced hepatitis. Liver function tests should be performed before starting Sotoxen and every 3 weeks for the first 3 months, then once a month. Liver function tests should include AST, ALT, and bilirubin levels.2 Patients should be instructed to report signs or symptoms of liver dysfunction such as abdominal pain, jaundice, dark urine, or itching to their oncology team. Sotoxen should be held if a patient develops grade 2, 3, or 4 hepatotoxicity until the symptoms resolve to a grade 1 or better, and then resumed at a lower dose.Interstitial Lung Disease: Although ILD was rare, several trial participants developed the condition. Patients should be evaluated regularly for respiratory symptoms such as shortness of breath, cough, and fever, and should be encouraged to quickly report these symptoms to their healthcare team. If ILD is suspected, Sotoxen should be held while the patient undergoes work-up for their symptoms.
সতর্কতা ও নিষেধাজ্ঞা
সতর্কতা ও সাবধানতা
Hepatotoxicity: Sotoxen can cause hepatotoxicity, which may lead to drug-induced liver injury and hepatitis. Among 357 patients who received Sotoxen in Code BreaK 100, hepatotoxicity occurred in 1.7% (all grades) and 1.4%. (Grade 3). A total of 18% of patients who received Sotoxen had increased alanine aminotransferase (ALT)/increased aspartate aminotransferase (AST); 6% were Grade 3 and 0.6% were Grade 4. The median time to first onset of increased ALT/AST was 9 weeks (range: 0.3 to 42). Increased ALT/AST leading to dose interruption or reduction occurred in 7% of patients. Sotoxen was discontinued due to increased ALT/AST in 2.0% of patients. In addition to dose interruption or reduction, 5% of patients received corticosteroids for the treatment of hepatotoxicity.Monitor liver function tests (ALT, AST, and total bilirubin) prior to the start of Sotoxen, every 3 weeks for the first 3 months of treatment, then once a month or as clinically indicated, with more frequent testing in patients who develop transaminase and/or bilirubin elevations. Withhold, dose reduce or permanently discontinue Sotoxen based on severity of adverse reaction.Interstitial Lung Disease (ILD)/Pneumonitis: Sotoxen can cause ILD/pneumonitis that can be fatal. Among 357 patients who received Sotoxen in CodeBreaK 100, ILD/pneumonitis occurred in 0.8% of patients, all cases were Grade 3 or 4 at onset, and 1 case was fatal. The median time to first onset for ILD/pneumonitis was 2 weeks (range: 2 to 18 weeks). Sotoxen was discontinued due to ILD/pneumonitis in 0.6% of patients. Monitor patients for new or worsening pulmonary symptoms indicative of ILD/pneumonitis (e.g., dyspnea, cough, fever). Immediately withhold Sotoxen in patients with suspected ILD/pneumonitis and permanently discontinue Sotoxen if no other potential causes of ILD/pneumonitis are identified.